FeMike,
The 1a and 1b buildout creates about 1,000 artisan treatment patient capacity per year after downtime for maintenance included. The 10X is based on full buildout, not same space, as I recall and that buildout has not begun yet. Considering any combo trial will likely be international in scope again, for the sake of more rapid enrollment, and that US centers will likely want a U.S. based manufacturing center with local leukopheresis done vs export/import and leuk done in the UK there would seem to be need for a North American supplier. Still think UK can handle it all? Best wishes.
Market Data 
Markets 
AI
